Tradestie Institutional Equity Comparison Engine

SYRE vs EWTX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

EWTX Overall Edge

EWTX Captures Institutional Edge (3โ€“1 Pillars ยท 2โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Edgewise Therapeutics, Inc. Common Stock (EWTX) driven by superior Valuation, Growth & Margin, Options & Structure while SYRE counters with relative strength in Momentum & Technical. Fundamentally, SYRE trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus EWTX at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, SYRE sits in UNCLASSIFIED (10th %ile IV; Dealer Gamma Walls on Pro) against EWTX sits in CONSOLIDATION (17th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner EWTX
SYRE N/M vs EWTX N/M Fwd P/E
Growth & Margin Winner EWTX
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner SYRE
1Y +341.7% vs +113.6% ยท 52W Pos 88% vs 82%
Options & Structure Winner EWTX
UNCLASSIFIED (10th %ile IV) vs CONSOLIDATION (17th %ile IV)
SYRE NASDAQ
Spyre Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$99.97
-3.88% 1D
Market Cap $9.8B
1M Return +25.11%
1Y Return +341.74%
Forward P/E N/M
Unified AI Score
36.1 / 100 SELL
Tech 8.0 Fund 33.0 Flow 50.0 Mom 50.0
EWTX NASDAQ
Edgewise Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$43.61
-5.05% 1D
Market Cap $5.0B
1M Return +17.26%
1Y Return +113.57%
Forward P/E N/M
Unified AI Score
33.6 / 100 SELL
Tech 8.0 Fund 38.0 Flow 66.0 Mom 44.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: SYRE +341.74% EWTX +113.57% Spread: +228.17 pp (SYRE Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
SYRE TTM Op. Margin: 0.0% EWTX TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SYRE vs EWTX. Trailing 12-month operating profitability (SYRE 0.0% vs EWTX 0.0%) and valuation multiples (SYRE N/M vs EWTX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: SYRE (4) vs EWTX (2)
Institutional Metric SYRE EWTX Criterion Row Winner
Market Capitalization Scale $9.8B $5.0B Larger Scale SYRE
Trailing P/E Ratio Valuation N/M 5.5x Lower Multiple EWTX
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +0.0% Higher Growth Tie
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -35.0% 92.1% Higher ROE EWTX
52-Week Range Position Momentum 88% ($22โ€“$111) 82% ($20โ€“$49) Stronger Trend SYRE
Beta / 30D Volatility Risk Regime 1.75ฮฒ ยท 59% Vol 1.19ฮฒ ยท 74% Vol Lower Realized Risk SYRE
Unified Institutional Score Composite Signal 36.1 / 100 (SELL) 33.6 / 100 (SELL) Higher Composite SYRE

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full SYRE vs EWTX Buy Guide
SYRE UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live SYRE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
EWTX CONSOLIDATION
91d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 17th %ile
IV Regime Compressed (<25th %ile)
Live EWTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither SYRE nor EWTX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.